Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell,
Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell, install, and service OpTxTools software worldwide as a stand-alone product for medical oncology practices and as part of its VARiS software for coordination with radiation oncology. With this acquisition, Varian is able to offer an integrated single software system for managing and coordinating radiation therapy and chemotherapy routinely used in the treatment of cancer, according to the company. The acquisition is expected to add annualized revenues of $9 million to Varian coffers and be nearly neutral to earnings for the company in fiscal year 2004.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.